Beheading giants: Germany takes aims at big drugs’ prices first
This article was originally published in Scrip
Think your drug has blockbuster potential? Well, think again if you are looking to Germany for a big chunk of that, especially if your product has a long patent life ahead of it. The new German reimbursement system is about to start grinding its teeth again, but this time it is older drugs that will be in the firing line. And the bigger their sales potential, the more likely they are to be hit. German reimbursement authorities seem to be deliberately targeting high-cost, high-volume drugs: the more potential a drug has, the higher it is up the hit list.
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.